Header Logo

Connection

CHRISTIE BALLANTYNE to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Diabetes Mellitus, Type 2.
CHRISTIE BALLANTYNE
Connection Strength
2.854
Diabetes Mellitus, Type 2
  1. Intensive Lifestyle Intervention, Cardiac?Biomarkers, and Cardiovascular?Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study. J Am Coll Cardiol. 2025 Feb 11; 85(5):489-500.
    View in: PubMed
    Score: 0.474
  2. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017 03; 19(3):19.
    View in: PubMed
    Score: 0.278
  3. Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. Circulation. 2017 02 21; 135(8):720-723.
    View in: PubMed
    Score: 0.277
  4. A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure. ESC Heart Fail. 2024 Apr; 11(2):1086-1096.
    View in: PubMed
    Score: 0.112
  5. Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study. PLoS One. 2023; 18(6):e0285259.
    View in: PubMed
    Score: 0.107
  6. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.107
  7. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
    View in: PubMed
    Score: 0.105
  8. Long-Term Effectiveness of the TIME Intervention to Improve Diabetes Outcomes in Low-Income Settings: a 2-Year Follow-Up. J Gen Intern Med. 2022 09; 37(12):3062-3069.
    View in: PubMed
    Score: 0.098
  9. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.098
  10. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.097
  11. Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Res Care. 2021 08; 9(1).
    View in: PubMed
    Score: 0.094
  12. Biomarker-Based Risk Prediction of Incident Heart?Failure in Pre-Diabetes and?Diabetes. JACC Heart Fail. 2021 03; 9(3):215-223.
    View in: PubMed
    Score: 0.091
  13. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
    View in: PubMed
    Score: 0.086
  14. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.076
  15. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017 01 03; 127(1):43-54.
    View in: PubMed
    Score: 0.069
  16. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.068
  17. Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
    View in: PubMed
    Score: 0.054
  18. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013 Jul 09; 12:100.
    View in: PubMed
    Score: 0.054
  19. Application of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetes. J Am Soc Echocardiogr. 2013 Aug; 26(8):901-909.e1.
    View in: PubMed
    Score: 0.054
  20. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013 May; 21(5):944-50.
    View in: PubMed
    Score: 0.053
  21. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012; 8(3):e1002607.
    View in: PubMed
    Score: 0.049
  22. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
    View in: PubMed
    Score: 0.046
  23. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Nov; 33(11):2297-303.
    View in: PubMed
    Score: 0.044
  24. Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
    View in: PubMed
    Score: 0.042
  25. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Jan; 33(1):197-9.
    View in: PubMed
    Score: 0.042
  26. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia. 2007 Jan; 50(1):36-42.
    View in: PubMed
    Score: 0.034
  27. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007 Aug; 193(2):283-91.
    View in: PubMed
    Score: 0.034
  28. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931.
    View in: PubMed
    Score: 0.029
  29. Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance. Nat Commun. 2021 03 26; 12(1):1927.
    View in: PubMed
    Score: 0.023
  30. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
    View in: PubMed
    Score: 0.021
  31. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.021
  32. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.